Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in navigating challenges like ...

Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025) ...

The fight for dominance between Regeneron and Bayer’s big blockbuster eye drug Eylea and Roche’s rival Vabysmo is playing out ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the condition. Sometimes, the better option might be surgery, corrective wear, or ...

In rare cases, more serious eye problems, like a detached retina, can occur. Aflibercept (Zaltrap and Eylea): Recommended for wet AMD, this drug's main benefit is that it requires less frequent ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex landscape of challenges and opportunities in recent months. According to ...

The European Commission's decision on approval is expected in the second half of January 2025. Eylea is used to treat neovascular age-related macular degeneration and other severe retinal diseases.

"These findings illuminate a critical mechanism that connects local synaptic activity to the broader gene expression changes necessary for learning and memory," said Mark Dell'Acqua, professor of ...

The international team describes their results and the underlying molecular mechanism in Cell Metabolism. Ergothioneine is a natural compound found in certain fungi such as oyster or shiitake ...